Skip to main content
main-content

12-02-2021 | ASCO GU 2021 | Conference coverage | Video

EV-301: Enfortumab vedotin boosts advanced urothelial cancer survival

Thomas Powles outlines the primary results of the phase 3 EV-301 trial comparing enfortumab vedotin with chemotherapy in patients who have received prior treatment for locally advanced or metastatic urothelial carcinoma (4:37).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

Read transcript

Image Credits